Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Proton Pump Inhibitor Use And Risk Of Colorectal Cancer: A Population-based, Case-control Study.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Proton Pump Inhibitor Use And Risk Of Colorectal Cancer: A Population-based, Case-control Study.

    • Related Experiment Videos

    Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.

    Douglas J Robertson1, Heidi Larsson, Søren Friis

    • 1VA Medical Center, White River Junction, VT 05009, USA. Douglas.robertson@med.va.gov

    Gastroenterology
    |August 7, 2007

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Proton pump inhibitor (PPI) use was not associated with an increased risk of colorectal cancer (CRC) in a large Danish population-based study. Findings indicate that PPIs do not measurably elevate CRC risk in clinical practice.

    Related Experiment Videos

    Area of Science:

    • Gastroenterology
    • Oncology
    • Pharmacoepidemiology

    Background:

    • Proton pump inhibitors (PPIs) are linked to elevated serum gastrin levels.
    • Hypergastrinemia may promote colorectal mucosa proliferation and increase colorectal cancer (CRC) risk.
    • Previous associations suggest a potential link between PPI use and CRC.

    Purpose of the Study:

    • To investigate the association between proton pump inhibitor (PPI) use and the risk of developing colorectal cancer (CRC).
    • To assess whether long-term or high-intensity PPI use increases CRC risk in a large population-based cohort.

    Main Methods:

    • A large population-based study conducted in North Jutland County, Denmark, from 1989-2005.
    • Incident colorectal cancer (CRC) cases (n=5589) were identified and compared with approximately 10 controls per case (n=55,890) using risk set sampling.
    • Proton pump inhibitor (PPI) use was determined from prescription data and analyzed using conditional logistic regression, adjusted for covariates.

    Main Results:

    • No evidence of increased colorectal cancer (CRC) risk was observed when comparing ever-users to never/rare users of PPIs (adjusted OR, 1.11; 95% CI, 0.97-1.27).
    • Neither short-term nor long-term (>7 years) high-intensity PPI users showed an increased CRC risk compared to never/rare users (adjusted ORs between 1.07-1.09).

    Conclusions:

    • Proton pump inhibitor (PPI) use in clinical practice is not associated with a measurable increase in colorectal cancer (CRC) risk.
    • The findings suggest that PPIs can be used without significantly elevating CRC risk.